Biosimilar medicines’ developments are maintaining their momentum and the 2016 Biosimilars Conference programme delves into strategic discussions regarding:

• Market and regulatory developments in the EU and globally, enlightened by the perspective of healthcare professionals’ and patients’ experiences
• Pharmacovigilance and clinical practice - what can be learned from the emerging data?
• The impact of biosimilar medicines on the competitive landscape of biological products, in light of 10 years of market existence

As the 4th conference of its kind, the 2016 programme gives a complete 360-degree overview of biosimilar medicines. Participants will leave the conference with a wealth of new information and an expanded network of contacts.

Media Partner

Generics and Biosimilars Initiative (GaBI) was founded in 2008. GaBI aims to foster the worldwide efficient use of high quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable and sustainable health care. GaBI Online (www.gabionline.net) is a one-stop portal for global news on recent developments in the field of generics and biosimilars, a repository of worldwide guidelines and an archive of related scientific information.

GaBI Journal – official Journal of the Generics and Biosimilars Initiative (http://www.gabionline.net) – is an independent, peer reviewed academic Journal. It encompasses all aspects of generic and biosimilar medicines development and use, from fundamental research to clinical application and policies.

GaBI’s mission – Building trust in cost-effective treatments Ltang@gabionline.net - www.gabionline.net / www.gabi-journal.net